What would it cost to license or adopt this technology?+
The project was funded with EUR 4,589,507 in EU contributions across 14 partners. Licensing terms would need to be negotiated directly with the consortium, led by Université Lyon 1. Based on available project data, no public pricing model has been disclosed.
Can this scale to large patient populations?+
The platform was built on cloud architecture specifically designed to collect multiparametric data from multiple sensor types (breath, saliva, ECG, blood pressure, activity, weight, nutrition). The system supports multiple user roles — patients, doctors, caregivers, nutritionists, fitness experts, and insurers. Scaling would depend on cloud infrastructure capacity and regulatory clearance in target markets.
Who owns the intellectual property?+
IP is distributed among the 14 consortium partners from 6 countries (DE, EL, ES, FR, IT, PT), coordinated by Université Lyon 1 in France. With 8 industry partners and 5 SMEs in the consortium, commercial licensing arrangements likely exist. Specific IP terms would need to be discussed with the coordinator.
Does this meet medical device regulations?+
The project delivered a technically tested and quality-assured integrated platform (D8.2). However, full medical device certification (e.g., CE marking under MDR) status is not confirmed in the available deliverable data. Any commercial deployment would require regulatory clearance for the biosensor components.
How long would integration take?+
The project ran from 2015 to 2018 and produced 12 deliverables including the final integrated platform. The modular architecture — separate sensor kit, smartphone app, and cloud backend — suggests components could be integrated individually. Based on available project data, a phased integration approach would be most practical.
What clinical evidence supports this?+
The project targeted patients with chronic and acute heart failure, including post-ischemic and dilated cardiomyopathy cases requiring hospital readmission. The final deliverable (D8.2) includes evaluation of technical testing of the integrated platform. Specific clinical outcome data would need to be requested from the consortium.
What happened after the project ended in 2018?+
The project closed in March 2018. With 5 SMEs and 57% industry ratio in the consortium, there was strong commercial intent. Based on available project data, follow-up commercialization status should be verified directly with the coordinator at Université Lyon 1.
